期刊文献+

银杏达莫治疗冠脉慢血流的临床研究 被引量:5

在线阅读 下载PDF
导出
摘要 目的:观察银杏达莫对慢血流的改善情况及临床疗效。方法:选取我院2007年7月至2009年7月疑诊冠心病,后行冠脉造影判断为慢血流患者(共60例),将其随机分为A、B两组各30例,A组常规内科药物治疗基础上加用银杏达莫注射液,每天20mL,共15d,并口服维持量治疗3个月,B组接受常规内科药物治疗。随访3个月后复查冠脉造影观察冠脉血流情况及心绞痛缓解情况。应用统计学方法比较两组间各项临床指标的差异。结果:两组患者在性别、年龄、心率、血压、血糖、血脂、凝血时间等临床指标方面无统计学差异;A组患者26例(86.7%)心绞痛症状及冠脉TIMI血流均得到明显提高,无心血管事件发生;B组患者中15例(50.0%)心绞痛症状及冠脉血流得到改善,但有2例急性冠脉综合征急诊入院。结论:银杏达莫可以改善慢血流患者的临床症状及血流,并降低心血管事件发生率。
出处 《实用医学杂志》 CAS 北大核心 2010年第16期3028-3030,共3页 The Journal of Practical Medicine
  • 相关文献

参考文献10

  • 1陆再英,钟南山.内科学[M].7版.北京:人民卫生出版社,2008:717-718.
  • 2Gibson C M, Cannon C P, Daley W L, et al. TIMI frame count: a quantilative methoal of assessing coronary artery flow [J]. Circulation , 1996,93(5) :879-888.
  • 3Beltrame J F, Limaye S B, Horowitz J D, et al . The coronary slow phenomenon : a new coronary microvascular disorder [J]. Cardiology, 2002,97(3) : 197-203.
  • 4刘永春.银杏达莫注射液治疗冠心病心绞痛60例临床观察[J].临床和实验医学杂志,2007,6(10):49-49. 被引量:8
  • 5Mangieri E, Macchiarelli G, Ciavolella M, et al . Slow coronary flow :clinical and histopathological features in patients with otherwise normal epicardial coronary arteries [J]. Cathet Cardio- vasc Diagn, 1996,37(4) : 375-381.
  • 6Cakmak M, Tanriverdi H, Cakmak N, et al. Simvastation maimprove uyoeardial perfusion abnormality in slow coronary flow [ J ]. Cardiology, 2008,110 ( 1 ) : 39-44.
  • 7Mosseri M, Yarom R, Gotsman M S, et al. Histologic evidence for small-vessel coronary artery disease in patients with angina and patent large coronary arteries [J]. Circulation, 1986,74(5) : 964-972.
  • 8Erdogan D, Caliskan M, Gullu H, et al. Coronary flow reserve is impaired in patients with slow coronary flow [J]. Atherosclerosis, 2007,191 ( 1 ) : 168-174.
  • 9Beltrame J F, Turner S P, Leslie S L, et al. The angiographic and clinical benefits of mibefradil in the coronary slow phenomenon [J]. J Am Coll Cardiol, 2004,44(2):57-62.
  • 10于燕,张冬平.银杏达莫注射液与奥德金注射液治疗脑梗死临床疗效对比分析[J].实用药物与临床,2009,12(1):67-68. 被引量:12

二级参考文献6

共引文献637

同被引文献85

  • 1李小芬,卫海松,贺会刚.芪参胶囊治疗冠脉慢血流的临床研究[J].基层医学论坛,2011,15(S1):3-4. 被引量:3
  • 2杨跃进,赵京林,荆志成,吴永健,尤士杰,杨伟宪,孟亮,田毅,陈纪林,高润霖,陈在嘉.中药通心络对猪急性心肌梗死再灌注后无再流的影响[J].中华医学杂志,2005,85(13):883-888. 被引量:34
  • 3黄敬泽,邱晓萍,王健.循环内皮细胞水平与糖尿病肾病的相关性及银杏达莫的干预作用[J].中国临床药理学与治疗学,2006,11(11):1309-1312. 被引量:10
  • 4董鹏,靳维华,王斌.通心络胶囊治疗冠状动脉慢血流的临床研究[J].北京中医药大学学报,2007,30(7):498-500. 被引量:8
  • 5Romano M, Buffoli F, Tomasi L, et al. The no -reflow phenomenon in acute myocardial infarction after primary angioplasty : incidence, predictive factors, and long - term outcomes [J]. J Cardiovasc Med (Hagerstown), 2008,9(1) : 59-63.
  • 6Valero S J, Moreno R, Reyes R M, et al. Pharmacologi- cal approach of no - reflow phenomenon related with per- cutaneous coronary interventions [ J ]. Cardiovasc Hematol Agents Med C hem, 2008,6 (2) : 125 - 129.
  • 7Kaul S. The "no reflow" phenomenon following acute my- ocardial infarction: mechanisms and treatment options [J]. J Cardiol,2014,64(2) : 77 -85.
  • 8Cakici M, Cetin M, Balli M, et al. Predictors of thrombus burden and no - reflow of infarct - related ar- tery in patients with ST - segment elevation myocardial infarction : importance of platelet indices [ J ]. Blood Co- agul Fibrinolysis, 2014,25 ( 7 ) : 709 - 715.
  • 9Dogan N B, Ozpelit E, Akdeniz S, et al. Simple clinical risk score for no -reflow prediction in patients undergo- ing primary Percutaneous Coronary Intervention with a- cute STEMI[J]. Pak J Med Sci,2015,31 (3) : 576 - 581.
  • 10Li J, Wu L, Tian X, Zhang J, et al. Intravascular ultra- sound observation of the mechanism of no - reflow phe- nomenon in acute myocardial infarction [ J ]. PLoS One, 2015,10(6) :e0119223.

引证文献5

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部